Contract Services Clinical Research
Hangzhou Qihan Biotech Co., Ltd. ("Qihan" or "Qihan Biotech" or "the Company"), an industry leader in applying multiplexable genome editing technology to c...
June 18, 2026 | News
Gesynta Pharma AB, a Swedish clinical stage pharmaceutical company focusing on chronic inflammatory diseases, today announced that 50% of the target of 190...
June 18, 2026 | News
Pelago Bioscience, a specialist drug discovery focused contract research organization (CRO), known for its industry-leading cell-based target engagement as...
June 17, 2026 | News
BRUIN CLL-322 is the first Phase 3 study to demonstrate superiority over a venetoclax-containing control arm in CLL, and, with the...
June 16, 2026 | News
QingSong Health Corp (2661.HK) and Basel Medical Group Ltd announced the signing of a Memorandum of Strategic Cooperation. The two parties i...
June 15, 2026 | News
Elixiron Immunotherapeutics (TPEx: 7871), a clinical-stage biopharmaceutical company pioneering precision immunotherapy for neurodegenerative and autoimmun...
June 15, 2026 | News
-- Lifespan Vision Ventures (LVV), an investment firm focused on therapeutics that improve human healthspan, congratulates its portfolio company Rejuvenate...
June 15, 2026 | News
Akeso, Inc. announced that the National Medical Products Administration (NMPA) of China has approved gumokimab (AK111), the company's internally-devel...
June 15, 2026 | News
Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on autoimmune and inflammatory diseas...
June 12, 2026 | News
Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics i...
June 12, 2026 | News
Follows initiation of Phase 1a/1b study in the U.S. Adcentrx intends to include clinical centers in China to broaden geographic repr...
June 10, 2026 | News
Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that its independently...
June 08, 2026 | News
Civorebrutinib is an investigational oral, covalent reversible BTK inhibitor designed to provide differentiated efficacy, safety and convenience in immun...
June 04, 2026 | News
Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases, ...
June 02, 2026 | News
Most Read
Bio Jobs
News
Editor Picks